| Species |
Human |
| Protein Construction |
IL-1 Beta/IL-1F2 (Ala117-Ser269)
Accession # P01584 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by SECHPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-1 Beta/IL-1F2, His & Avi, Human at 5μg/ml (100μl/Well) on the plate can bind Human IL1R2, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
20.1 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 20.1 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin-1 beta (IL-1β) is induced by inflammatory signals in a broad number of immune cell types. IL-1β (and IL-18) are the only cytokines which are processed by caspase-1 after inflammasome-mediated activation. IL-1 signaling activates innate immune cells including antigen presenting cells, and drives polarization of CD4 T cells towards T helper type (Th) 1 and Th17 cells. |
| Synonyms |
Interleukin-1 beta; IL-1 beta; IL1F2; IL1B; IL-1BETA; IL1F2; IL-1β; IL-1 beta; IL-1B ;Interleukin-1 β; IL-1 β; IL-1β; IL-1 β |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
